Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析

◆英語タイトル:Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15776
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:78
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,625見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,875見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Eli Lilly and Co (LLY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. It also provides pet medicine, food-safety products and companion animal health products, besides services to the food animal industry. Lilly also has mid-to-late stage pipeline products. The company distributes human pharmaceutical and animal health products through independent wholesale distributors. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

Mar 28,2019 Lilly and ImmuNext enter autoimmune disease research alliance
Mar 20,2019 NCCN announces six quality improvement projects in Gastric Cancer care approved for collaboration with Lilly Oncology
Mar 04,2019 Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price
Feb 18,2019 Lilly closes $8bn Loxo Oncology acquisition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Eli Lilly and Co – Key Facts
Eli Lilly and Co – Key Employees
Eli Lilly and Co – Key Employee Biographies
Eli Lilly and Co – Major Products and Services
Eli Lilly and Co – History
Eli Lilly and Co – Company Statement
Eli Lilly and Co – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Eli Lilly and Co – Business Description
Business Segment: Animal Health
Overview
Performance
Business Segment: Human Pharmaceuticals
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other Foreign Countries
Performance
Geographical Segment: United States
Performance
R&D Overview
Eli Lilly and Co – Corporate Strategy
Eli Lilly and Co – SWOT Analysis
SWOT Analysis – Overview
Eli Lilly and Co – Strengths
Eli Lilly and Co – Weaknesses
Eli Lilly and Co – Opportunities
Eli Lilly and Co – Threats
Eli Lilly and Co – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Eli Lilly and Co, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 28, 2019: Lilly and ImmuNext enter autoimmune disease research alliance
Mar 20, 2019: NCCN announces six quality improvement projects in Gastric Cancer care approved for collaboration with Lilly Oncology
Mar 04, 2019: Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price
Feb 18, 2019: Lilly closes $8bn Loxo Oncology acquisition
Feb 15, 2019: Bayer gains full rights to TRK inhibitors Vitrakvi, LOXO-195 as Eli Lilly completes Loxo Oncology deal
Feb 15, 2019: Hagens Berman: Judge Denies Insulin Makers’ Motion to Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices
Feb 13, 2019: Drugs targeting metastatic cancers, opioid addiction are among additional specialty drugs available through AllianceRx Walgreens Prime
Feb 06, 2019: Lilly reports strong fourth-quarter and full-year 2018 financial results, lowers 2019 EPS guidance to reflect the pending acquisition of loxo oncology
Jan 31, 2019: Sanofi, Lilly and Novo face enquiry over high insulin prices in US
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Eli Lilly and Co, Key Facts
Eli Lilly and Co, Key Employees
Eli Lilly and Co, Key Employee Biographies
Eli Lilly and Co, Major Products and Services
Eli Lilly and Co, History
Eli Lilly and Co, Subsidiaries
Eli Lilly and Co, Joint Venture
Eli Lilly and Co, Key Competitors
Eli Lilly and Co, Ratios based on current share price
Eli Lilly and Co, Annual Ratios
Eli Lilly and Co, Annual Ratios (Cont...1)
Eli Lilly and Co, Annual Ratios (Cont...2)
Eli Lilly and Co, Interim Ratios
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Eli Lilly and Co, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Eli Lilly and Co, Performance Chart (2014 - 2018)
Eli Lilly and Co, Ratio Charts
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Biomedical Structures LLC:(医療機器分野)企業M&A及び提携動向
    Summary Biomedical Structures LLC (BMS) is a medical textile manufacturer. The company designs, develops and manufactures medical textiles for device manufacturers in the orthopedic, cardiovascular, general surgery, and tissue engineering and regenerative medicine markets. It offers structures such …
  • Bankinter, S.A.:企業のM&A・事業提携・投資動向
    Bankinter, S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bankinter, S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Ban Leong Technologies Ltd (B26):企業の財務及び戦略的SWOT分析
    Summary Ban Leong Technologies Ltd (Ban Leong) is a technology company that distributes IT products such as computer peripherals, accessories and other multimedia products. The company’s products include audio and video products, communication devices, computer components, memory disks and storage d …
  • FINAM Investment Holding:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' FINAM Investment Holding Merger …
  • Supreme Petrochem Ltd (SUPPETRO):企業の財務及び戦略的SWOT分析
    Summary Supreme Petrochem Ltd (SPL) is a chemical company that manufactures and sells polystyrene products. The company offers products such as general purpose polystyrene, high impact polystyrene, master batches, specialty polystyrene, FR-hips, toughened PS, extruded polystyrene and compound polyst …
  • Mendes Junior Trading E Engenharia SA:企業の戦略・SWOT・財務情報
    Mendes Junior Trading E Engenharia SA - Strategy, SWOT and Corporate Finance Report Summary Mendes Junior Trading E Engenharia SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Warren Resources, Inc. (WRES):企業の財務及び戦略的SWOT分析
    Summary Warren Resources, Inc. (Warren) is an oil and gas exploration company that develops crude oil and natural gas. The company primarily focuses on the exploration and development of waterflood oil recovery properties in the Wilmington Field in the Los Angeles Basin of California. It consists of …
  • Unisplendour Guhan Group Corporation Ltd (000590):企業概要、財務及び戦略的SWOT分析
    Summary Unisplendour Guhan Group Corporation Limited (Unisplendour) is a pharmaceutical company. The company manufactures and markets pharmaceutical products. Its products include chinese medicines and chinese healthcare products, such as medicines for cold treatment and anti hyperlipemia medicines. …
  • LifeAssays AB (LIFE B):企業財務及び戦略的SWOT分析
    Summary LifeAssays AB (LifeAssays) is a medical device company which develops, manufactures and markets in-vitro diagnostic and veterinary care products. It offers point-of-care diagnostic testing systems. The company’s product portfolio comprises lifeassays human system and lifeassays veterinary sy …
  • Maersk Line AS:企業の戦略的SWOT分析
    Maersk Line AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • ARCA biopharma, Inc. (ABIO)(製薬・医療分野):企業M&A動向
    Summary ARCA biopharma, Inc. (ARCA biopharma) is a biopharmaceutical company. The company develops genetically-targeted therapies for the cardiovascular diseases. It focuses on develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. ARCA biopharma’s pr …
  • Academic Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Academic Medical Center (AMC), a subsidiary of University of Amsterdam is a medical center that offers research and educational services. The center offers services such as treatment of patients, medical research and medical education. It provides medical treatments and services for various …
  • The Hain Celestial Group, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' The Hain Celestial Group, Inc. …
  • React Energy Plc (REAC):企業のM&A・提携動向(発電分野)
    Summary React Energy Plc (React), formerly Kedco plc is a renewable energy company that identifies, develops, builds and operates renewable energy electricity and heat generation plants. The company's projects include 12MW Clay Cross Biomass CHP; 800kw Pluckanes Windfarm project; and Single wind tur …
  • SSY Group Ltd (2005):企業の財務・戦略的SWOT分析
    Summary SSY Group Ltd (SSY), formerly Lijun International Pharmaceutical (Holding) Co Ltd is a pharmaceutical company that offers range of pharmaceutical products such as intravenous infusion solution. The company offers glass bottle infusion solutions, non-PVC soft bag infusions, and PP plastic bot …
  • Vyome Biosciences Pvt Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Vyome Biosciences Pvt Ltd (Vyome) is a research center that develops drugs for antibiotics-resistant acne and other opportunist pathogens. The center’s platforms modify active agents based on genomic information of the disease causing micro organism. Its pro-drug platform develops therapeuti …
  • Paragon Union Berhad:企業の戦略・SWOT・財務分析
    SummaryParagon Union Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Fi …
  • Pike Electric Corporation (PIKE):企業概要、財務及び戦略的SWOT分析
    Summary Pike Electric Corporation (Pike) is an energy solution provider. The company provides construction, engineering and maintenance for transmission powerlines and substations. It offers energy solutions such as engineering, substation, transmission, distribution, thermal rate, renewable energy, …
  • Derma Sciences Inc (DSCI):企業のM&A・提携動向(医療機器分野)
    Summary Derma Sciences Inc (Derma Sciences) is a medical devices company. It focuses on advanced wound care and traditional wound care. Its advanced wound care product portfolio includes dermagran, silverseal, alginate dressing, aquasite hydrogel, primacol hydrocolloid, hydrocell foam and primaderm …
  • Turcas Petrol A.S. (TRCAS):企業概要、財務及び戦略的SWOT分析
    Summary Turcas Petrol A.S. (Turcas) is a fuel distribution company. The company operates in the fields of fuel distribution, oil refining, power generation and trading, and import and wholesale of natural gas. It offers lubricant exchange services, and lubricants and fuel distribution retailing serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆